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Background 
To date, there are no data from randomized controlled studies on the benefit of cardiac resynchronization 
therapy (CRT) when implanted as an upgrade in patients with a previous device as compared to de novo 
CRT. In the CRT Survey II we compared the baseline data of patients upgraded to CRT (CRT-P/CRT-D) 
from a previous pacemaker (PM) or implantable cardioverter-defibrillator (ICD) to de novo CRT 
implantation.  
Methods and results 
In the European CRT Survey II, clinical practice data of patients undergoing CRT and/or ICD implantation 
across 42 European Society of Cardiology (ESC) countries were collected between October 2015 and 
December 2016. Out of a total of 11ര088 patients, 2396 (23.2%) were upgraded from a previous PM or 
ICD and 7933 (76.8%) underwent de novo implantation. Compared to de novo implantations, upgraded 
patients were older, more often male, more frequently had ischaemic heart failure aetiology, atrial 
fibrillation, reduced renal function, worse heart failure symptoms, and higher N-terminal pro-B-type 
natriuretic peptide levels. Upgraded patients were more often PM-dependent and less frequently received 
CRT-D. Total peri-procedural, in-hospital complications and length of hospital stay were similar. Upgraded 
patients were less frequently treated with heart failure medication at discharge.  
Conclusion 
Despite a lack of evidenced-based data, close to one quarter of all CRT implantations across 42 ESC 
countries were upgrades from a previous PM or ICD. Despite older age and worse symptoms, the CRT 
implantation procedures in upgraded patients were equally frequently successful and complications 
similar to de novo implantations. These results call for more studies.  
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I nt roduct ion  
 
Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure (HF) 
with a reduced left ventricular ejection fraction (LVEF) and electrical dyssynchrony.14 Prospective 
randomized trials on CRT have consistently demonstrated reductions in HF-related hospitalization and 
mortality rates among patients with a broad spectrum of symptomatic HF57 and in HF patients expected 
to be dependent of right ventricular (RV) pacing.8 Despite class IA recommendation in international 
guidelines,9,10 therapy implementation has been slow and unevenly distributed across Europe.11  
In the first CRT survey conducted between 2008 and 2009 in 13 European Society of Cardiology (ESC) 
countries, we established similar benefits by CRT in patient groups outside of randomized controlled trials 
(RCTs) such as >75 years or requiring an upgrade from a previous pacemaker (PM) or implantable 
cardioverter-defibrillator (ICD) who constituted one fourth of all patients.1214 This means that doctors 
selected patients for CRT in the belief that the benefits will be similar in patients who fulfil class IA 
recommendations to weaker or absent recommendations. Although nearly 10 years have passed, there 
still has not been a RCT with the focus on studying CRT benefits of patients upgraded to CRT vs. not 
being upgraded illustrating the need for clinical trials.  
In the European CRT Survey II,15 data on clinical practice of CRT and/or ICD implantation across 42 
ESC countries were collected between October 2015 and December 2016 with regard to patient 
characteristics, implantation procedures and complications with the aim to compare quality control and 
identify obstacles for therapy implementation in a large contemporary patient cohort. In this paper, we 
compare baseline patient data in patients undergoing upgrading to CRT compared to those subject to de 
novo CRT implantation.  
 
 
Methods  
 
Structure and recruitm ent , data collect ion, m anagem ent  and analysis  
 
The rationale15 and baseline results16 of the CRT Survey II have been published previously. This survey 
was designed as a joint initiative of the European Heart Rhythm Association (EHRA) and the Heart Failure 
Association (HFA). EHRA and HFA co-coordinated the survey with sponsorship from five device companies 
and from several drug and diagnostic companies (see Acknowledgements). The centres were asked to 
enrol consecutive new CRT implantations and upgrades from a previous PM or ICD to CRT whether or not 
they were successful between October 2015 and December 2016. Generator replacements were not 
included.  
Of 47 ESC countries identified from the EHRA Whitebook,11 42 agreed to participate. A total of 288 
implanting centres recruited patients. In order to achieve a cohort representative for each country, we 
aimed to include at least 10% of all CRT implantations performed in the respective geographical region 
during the survey time.  
The web-based electronic case record form (eCRF) used for data collection was developed by the 
Institut for Herzforschung Ludwigshafen (IHF).17 It included anonymized data on patient characteristics, 
clinical assessment, indications for CRT, including reason for upgrades, implant procedures as well as 
peri-procedural and in-hospital complications and adverse events during index hospitalization. The eCRF 
was reviewed by ESC data protection consultants to ensure patient anonymity. This, together with the 
fact that the survey did not include follow-up data after discharge, obviated the necessity for formal 
institutional review board approval in most countries. Most centres were simply required to notify their 
local or national ethics committee of their participation in the survey.  
 
Stat ist ical analysis  
 
All data analyses were performed by IHF using SAS®, release 9.3 (SAS Institute Inc., Cary, NC, USA) on 
a Microsoft® Windows® 7 Enterprise platform. All percentages are relative to the total number of patients 
with available information. Binary, categorical, and ordinal parameters were summarized by means of 
absolute and percentage numbers within the various categories. Numerical data were summarized by 
means of standard statistics (i.e. number of available data, mean, standard deviation, median, lower and 
upper quartile, i.e. interquartile range, 5th and 95th percentile). A P-value < 0.05 was considered 
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statistically significant. Non-parametric tests were used when appropriate. No imputation for missing data 
was made.  
 
 
Results  
 
A total of 11ര088 patients were recruited from 42 countries. These patients constituted 11% of expected 
implantation rate during the enrolment period. Most countries (34/42) included at least 10% of the 
expected total number of implants for that country. The majority of CRT implantations (82%) were 
performed in either university or teaching hospitals.  
For the purpose of this analysis, 757 patients were excluded due to missing data concerning reason 
for an upgrade to CRT. Thus, the total cohort in the present study was 10ര331 patients. Of these, 2398 
(23.2%) were upgraded from a previous PM (60.9%) or ICD (39.8%) and 7933 (76.8%) underwent de 
novo implantation (Table 1).  
 
Pat ient  character ist ics  
 
The baseline patient characteristics are presented in Table 1. Upgraded patients were 3 years older than 
de novo patients with a larger proportion (35%) having 75 years of age. Overall, there were few women 
in the survey. Moreover, only 18.8% of upgraded patients were women compared to 26.1% in the de 
novo recipients. Upgraded patients more often had a history of ischaemic heart disease, valvular heart 
disease or cardiac surgery, and more often had glomerular filtration rate <60 mL/kg/min. Moreover, they 
more often had atrial fibrillation (AF). Nearly half of both groups had a previous HF hospitalization within 
the last year. A minority of both groups participated in clinical trials. Patient characteristics of those 
excluded from the analysis did not differ significantly from the analysed patients, except that were more 
often PM-dependent (41.5%), had high-degree atrioventricular (AV) block (35.3%) and more often AF 
(27.1%).  
 
Pre- im plantat ion clinical evaluat ion and ECG (Table 2)  
 
In accordance with the greater presence of co-morbidities in the upgraded group, New York Heart 
Association (NYHA) functional class and N-terminal B-type natriuretic peptide (NT-proBNP) levels were 
both higher in upgraded patients indicating a worse HF disease state. Severity and presence of mitral 
regurgitation was also greater in upgraded patients. Significantly more patients were in AF in the 
upgraded cohort. High-degree AV block was present in 44.2% of upgraded patients compared to 10% in 
the de novo cohort, and 51.9% in the upgrade cohort were PM-dependent. Accordingly, a PM indication 
and expected dependence of RV pacing was a more common reason for upgrades, whereas HF with wide 
QRS was the most common reason for de novo CRT implantation. Notably, PM indication with an 
expected dependence on RV pacing was the main reason for CRT upgrade in 39% of upgraded patients 
compared to 17.4% of patients subject to de novo implantation. The paced QRS duration had a median 
value of 180 ms and an intrinsic value of 160 ms. The 1344 patients in the upgraded cohort had 
significantly longer intrinsic QRS durations than de novo patients. Left (LBBB) and right bundle branch 
block (RBBB) were more frequent bundle branch block morphologies in de novo and of indeterminable 
morphology in the upgraded group. An AV nodal ablation was planned in 52.4% and performed in 47.6% 
of AF patients subject to upgrades. Mechanical dyssynchrony was amongst indications for CRT 
implantation in >10% of patients in both groups. However, mechanical dyssynchrony was the sole 
indication for CRT only in 52 in the de novo CRT and 36 in the upgraded group.  
 
Cardiac resynchronizat ion therapy im plantat ion and peri- procedural com plicat ions (Table 3)  
 
Admission for CRT was elective in most cases, more commonly in the upgraded cohort. Only one fourth of 
patients were referred from other centres. Implantations were most often performed by 
electrophysiologists. The implantation was successful in 97.1% of the upgraded and 97.3% of the de 
novo patients. Overall, about one third of patients received a CRT-P and the rest CRT-D. CRT-P was more 
often selected for the upgraded cohort than for the de novo group. The median procedure time was 90 
min in both groups with slightly longer fluoroscopy time in the de novo implantations reflecting that more 
than one lead was implanted. Overall, multipolar left ventricular (LV) leads were more common than 
bipolar leads, although upgraded patients more commonly received bipolar LV lead and less often 
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multipolar leads. LV lead optimization by electrical delay was used in 66.5% of upgraded compared to 
59.4% of de novo patients. Optimization by measurement of the paced QRS duration was utilized in 
52.4% of upgraded compared to 62% of de novo patients, indicating that attempts were indeed being 
made to optimize LV lead position by inexpensive methods. The peri-procedural complication rate (Figure 
1) was 5.1% in the upgraded and 5.7% in the de novo cohort. Bleeding was more common in the 
upgraded group and pneumothorax in the de novo group. About one third in both cohorts experienced 
coronary sinus dissection. Very few patients had pericardial tamponade in both groups.  
 
Post - CRT im plantat ion data including adverse events, discharge status and follow  up (Table 4)  
 
Almost all patients in both groups were discharged alive after a median hospital stay of 3 days. However, 
there were 8 deaths in the upgraded cohort and 32 in the de novo cohort. The reasons for death were 
cardiovascular in all patients. Major adverse events occurred in 5.4% of upgraded and 4.4% de novo CRT 
recipients, with arrhythmia being the most common. The difference between CRT-paced and RV-paced 
QRS duration was 40 ms. For patients with pre-procedural intrinsic rhythm, the corresponding delta was 
20 ms. AV and ventriculoventricular optimization were very frequently undertaken in both cohorts. 
Device-based software was used to optimize programming in 31.1% of upgraded patients compared to 
37.6% of the de novo patients. Regarding the planned follow-up after discharge, more than 85% of both 
cohorts were scheduled for follow-up at the implantation centre and remote monitoring was planned in 
30%.  
Heart failure medications at discharge included loop diuretics in >80% and beta-blockers (89%). 
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were more 
commonly prescribed in de novo (87.4%) than in upgraded (83.7%) patients as were mineralocorticoid 
receptor antagonists (MRAs) (60.1% in upgrades compared to 64.6% in de novo patients). As expected 
from the much larger proportion of AF in the upgraded cohort, these patients were significantly more 
often anticoagulated (61.1%) compared to de novo (41.8%), most frequently with warfarin. In contrast, 
antiplatelet therapy was more common in the de novo cohort including dual or triple antiplatelet therapy.  
 
Com parison of pat ients upgraded to a CRT- P or CRT- D  (Table 5)  
 
Of the 2398 upgrade patients, 1506 were upgraded to a CRT-D and 818 to a CRT-P. We further 
separated our comparison to patients upgraded from a previous PM to CRT-P, from a previous PM to CRT-
D, and from a previous ICD to CRT-D. For this analysis we excluded 105 patients because of more than 
one previous device (either a PM or an ICD) ticked in the eCRF, a non-successful CRT implantation or 
missing information with regard to type of previous device.  
Patients upgraded from a PM to a CRT-P had a median age of 73.7 years and were older compared to 
patients upgraded to CRT-D. Moreover, 57% were older than 75 years and 28.7% were women. A non-
ischaemic aetiology was the most common HF aetiology. These patients were in worse NYHA class, and 
AF was more common than for patients upgraded from an ICD to CRT-D. Patients upgraded from a PM to 
a CRT-D had a median age of 70 years and 34.3% were older than 75 years with balanced distribution of 
HF aetiology. Previous valve surgery was more common in this group than in the other groups. Patients 
upgraded from an ICD to a CRT-D had a median age of 66.5 years and less often were women. They 
more often had ischaemic HF aetiology, previous myocardial infarction, a history of coronary 
interventions, and more often had chronic kidney disease. The median LVEF was lower in this group and 
a previous HF hospitalization more common. As expected, high-degree AV block and PM dependence was 
more common in patients upgraded from a PM than in those upgraded from an ICD. Although intrinsic 
QRS duration did not differ, patients upgraded from an ICD more commonly had a long PR interval. Peri-
procedural complications did not differ significantly between upgraded groups but those upgraded from a 
PM to a CRT-D more often developed bleeds requiring an intervention. Such patients also tended to have 
more postoperative complications and major adverse events reflecting the more complex procedure of 
addition of an ICD lead in addition to a LV lead. The median length of stay was longer in patients 
upgraded to CRT-D than to CRT-P. Regarding medication at discharge, patients upgraded from a PM to 
CRT-P received less HF medication and less often were planned to be followed by remote monitoring.  
 
Com parison of upgraded pat ients w ith int r insic rhythm  w ith upgraded pacem aker- dependent  
pat ients (online supplementary Table S1)  
 
Of upgraded patients, 1125 had intrinsic rhythm and 1213 were PM-dependent.  PM-dependent patients 
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were older and had ischaemic heart disease (41.9%) and non-ischaemic disease (46.2%) as primary 
aetiology, whereas ischaemic heart disease was a more common aetiology (54%) in non-PM-dependent 
patients. Thus, a prior myocardial infarction or coronary intervention was also more common in this 
cohort. Importantly, a history of valve surgery, in particular aortic valve replacement, was much more 
common in PM-dependent patients, possibly reflecting damage to the conduction system during valve 
surgery. Mitral valve replacements were more common in non-PM-dependent patients. As expected, 
secondthird degree AV block was predominantly found in PM-dependent patients. The PR interval was 
longer in non-PM-dependent patients and the median LVEF significantly lower.  
 
Benchm arking   
 
The device choice in upgraded patients amongst the 10 largest enrolment countries in the survey is 
shown in Figure 2. Slovakia and France chose a CRT-P in about half of the patients, whereas Turkey only 
implanted CRT-D devices. In Slovakia, 39% in upgraded vs. 43.5% in de novo CRT recipients had 
ischaemic HF aetiology and 35.4% in the upgraded group and 38.1% in the de novo group had a 
previous myocardial infarction. In France, 42.4% of upgraded vs. 36.2% in de novo CRT recipients had 
ischaemic HF aetiology and only 25.9% in the upgraded group and 22.4% in the de novo group had a 
previous myocardial infarction. In contrast, in Turkey, 56% in the upgraded group and 51.3% in the de 
novo group had ischaemic HF aetiology and 50% in the upgraded group and 41.5% in the de novo group 
had a previous myocardial infarction. Moreover, patients in Slovakia were on average 68.8 years old, in 
France 73.6 years old, and in Turkey 61.1 years old amongst upgrades. For the de novo group, Slovakian 
patients were 67.1 years old, French patients 71.0 years old, and Turkish 64.2 years old. Whether the 
younger age and more ischaemic heart disease in the Turkish cohort compared to Slovakia and France is 
the only explanation for primarily choosing CRT-D is not clear.  
 
 
Discussion  
 
Cardiac resynchronization therapy introduced in the late 1990s has been a valuable contribution to HF 
management. The evidence remains strongest in patients with LVEF <35%, sinus rhythm, with wide QRS 
and/or LBBB.9,10 In recent years it has also been established that CRT is not of value in narrow QRS 
(130 ms) and may even be harmful.18 However, not much new evidence has emerged concerning 
upgrades from a previous PM or ICD to a CRT. Our results indicate that clinicians disregard this gap of 
evidence and continue to upgrade a large number of patients. Upgrades constituted 28% of the cohort16 
and the same percentage in the previous survey.12 This proportion may indicate the firm belief by 
clinicians that CRT will be beneficial in these patient populations despite the absence of strong guideline 
indications.  
In contrast to CRT Survey I, there was no follow-up in the present survey. This simplification was 
intentional to enable many more countries to join and to collect a larger cohort representative of all ESC 
geographies. Therefore, this second and much larger survey provides a valuable source of clinical 
information across the ESC countries and provides feedback on adherence to existing guidelines, which in 
turn supports the development of future guidelines.  
In this survey, patients were older than in RCTs. They were rarely referred from another hospital, in 
particular for upgrades, indicating limited access to CRT outside of teaching or university hospitals. There 
were very few women overall in the survey and especially among those upgraded to CRT. This probably 
indicates under-implementation of therapy overall and in particular in women, which may call for specific 
actions. However, the true proportion of women with an indication for CRT may be influenced by the fact 
that women more often have HF with preserved ejection fraction.19 Previous studies indicate that CRT 
implementation is slow and that seeing a cardiologist or being treated at a HF clinic predicts being 
considered for CRT,20 thus underlining the need for HF specialist access across Europe. Our findings 
indicate that such access may be suboptimal. As expected, upgraded patients were also older and had 
more co-morbidities. Amongst patients upgraded, those upgraded from a PM to CRT-P were 7.2 years 
older than those upgraded from an ICD to CRT-D and more often women. CRT-P recipients less often had 
underlying ischaemic heart disease, which in part could explain this choice. Notably, upgraded patients 
who were PM-dependent had often had a previous aortic valve replacement, which may be indicative of 
previous conduction system damage. We do not have information if or to which extent the use of 
transcatheter aortic valve procedures contributed to this observation. Overall, guideline-indicated HF 
medication was suboptimal but comparable to that in a recent European HF registry.21 For example 
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almost 60% of upgraded compared to 64% of patients with presumably severe HF undergoing de novo 
CRT implantation were discharged with MRAs. Upgraded patients were somewhat less frequently taking 
ACE inhibitors or ARBs and were more often taking oral anticoagulants.  
A relatively large percentage (17.4%) of the de novo cohort received a CRT because they were 
expected to depend on RV pacing. This may reflect adoption of the ESC HFA 2016 guidelines,10 which 
state that CRT rather than RV pacing is recommended for patients with HF with reduced LVEF regardless 
of NYHA class or atrial rhythm, who have an indication for ventricular pacing due to high-degree AV block 
in order to reduce morbidity (class I recommendation, level of evidence A).7 This recommendation was 
published in the middle of the CRT Survey II, which may have influenced our results. Guideline criteria 
for CRT are based on symptoms, LVEF 35%, QRS duration and morphology and emphasize that HF 
medication should be optimized before considering CRT. In CRT Survey II, QRS duration was 120 ms in 
9.2% of patients upgraded to CRT and 7.3% of those in the de novo cohort, which is clearly outside of 
guideline recommendations. Some patients in the upgraded (6%) and in the de novo cohort (5.2%) had 
a QRS duration 120130 ms reflecting the 2013 EHRA guideline recommendation but not the 2016 ESC 
HFA guidelines that were published during the conduct of CRT Survey II.10 It cannot be ruled out that 
some of these patients were scheduled for an AV nodal ablation, which justified the short QRS duration at 
the time of implantation. Moreover, our results indicate that mechanical dyssychrony still remains 
amongst the selection criteria of physicians for CRT, though it is seldom the sole indication. Nonetheless, 
following the results of EchoCRT,18,22,23 these most recent guidelines indicate that CRT is contraindicated 
in patients with QRS <130 ms and that mechanical dyssynchrony is not an indication (class III 
recommendation, level of evidence A). In the first survey, there was similar 1-year mortality rates in 
patients upgraded compared to de novo CRT implantations. Most of the RCTs on CRT did not include 
patients with a previous device, except for the MUSTIC-AF24 and RAFT trials.7 In the small number of 
patients studied in these trials, all of whom had AF, only a small or no benefit was shown in patients 
upgraded from a previous PM25 or from a PM or ICD.26 The 2013 ESC EHRA guidelines on pacing and CRT 
gave a class I recommendation, level of evidence B9 for device upgrade for patients with persistent 
symptoms due to HF, but the most recent 2016 ESC HFA guidelines gave upgrades a class IIb 
recommendation, level of evidence B,10 underlining the lack of scientific evidence.  
Chronic RV pacing prolongs QRS duration and induces ventricular dyssynchrony. Previous studies have 
indicated that extent of RV pacing is linked to the subsequent development of HF in patients paced due to 
sinus node disease,25 or in ICD recipients with previous LV dysfunction in the DAVID trial.26 The 
relationship between extent of previous RV pacing defined as >40% and response to upgrading to CRT 
has been previously studied.27,28 Previously RV paced patients in one observational study27 responded 
better to CRT regarding LV function than those who had not experienced RV pacing. In addition, they had 
an adjusted 33% lower risk of death or HF while tending to have an adjusted lower risk of death than 
those not RV paced. The authors concluded that patients upgraded to CRT with prior RV pacing respond 
to CRT at least as well as de novo. However, the true cut-off for which extent and duration of RV pacing 
may be harmful has not been fully elucidated. These findings indicate that HF due to RV pacing may be 
easier to successfully treat with CRT than HF of other causes. In our survey we do not have information 
on the extent or duration of RV pacing in our patients upgraded to CRT, and hence have no information 
as to whether RV pacing had contributed to HF symptoms in our patients. But, in general, patients 
upgraded in this survey were in worse disease state regarding HF symptoms and had more AF, ischaemic 
HF, renal function impairment and were older, all of which contributed to HF development. In a recent 
meta-analysis, there was no significant difference in clinical response or mortality after CRT upgrade 
compared to de novo implantations.29  
These results and the wide use of upgrading in the current and previous survey call for the need for a 
clinical trial. A randomized study evaluating upgrading from a PM or an ICD to CRT vs. no upgrading 
could be a valid way to scientifically either support or refute the present extensive choice of upgrading 
demonstrated in this survey, despite lack of scientific evidence. The ongoing BUDAPEST-CRT Upgrade 
study30 may provide such evidence. In BUDAPEST-CRT, 360 patients with LVEF <25%, NYHA class IIIV 
with paced QRS duration 150 ms and RV pacing of 20% will be randomized to be upgraded to a CRT-D 
or an ICD or remain in ICD therapy. The primary endpoint is a composite of all-cause mortality, time to 
first HF hospitalization and 15% reduction in LV end-systolic volume at 12 months.  
It has been reported that there are more complications in upgrades from a previous device compared 
to new implantations from the Danish Pacemaker Registry31 and the US REPLACE Registry.32 However, in 
our first CRT survey, peri-procedural and in-hospital complications were similar in upgrades compared to 
de novo.14 Similarly, in the current survey, we did not find either peri-procedural or in-hospital device-
related complications to be different in upgrades compared to de novo patients despite worse HF disease 
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state and more co-morbidities in upgraded patients. However, the upgraded patient cohort had more 
bleeding complications during surgery, probably reflecting that they more often were on oral 
anticoagulants. De novo patients more often experienced lead-related complications, reflecting that they 
had more than one lead implanted instead of LV lead only. Taken together our results suggest no reason 
to stop physicians from considering upgrade to CRT and/or ICD in indicated patients due to fear of 
complications.  
 
Lim itat ions  
 
The strength and ability of a survey to address questions are related to the strength of its methodology, 
its representativeness and size. Overall, 11% of patients implanted with CRT in participating countries 
were enrolled in the survey. We cannot assess the degree of selection bias in the choice of enrolled 
patients or in the reporting of unsuccessful implants, complications and mortality rates. Moreover, the 
majority of participating centres were university and teaching hospitals. This is a limitation, since CRT 
implantations in the real word are also performed at smaller hospitals.  
Furthermore, the interpretation of questions in the eCRFs was up to the investigator. The IHF 
conducted front-end data check and post database lock quality control analyses designed to prevent 
incorrect data being analysed. It is difficult to quantify the effect of the most recent ESC HFA guidelines 
which were published during this survey. The adoption of new guidelines take time to be applied in 
clinical practice.33  
 
 
Conclusion  
 
Despite lack of evidence-based data, close to one fourth of all CRT implantations across ESC countries in 
the CRT Survey II of more than 11ര000 patients are upgrades from a previous PM or ICD. Upgraded 
patients had more co-morbidities and older age but similar implantation success and complication rates 
compared to de novo implantations. These results call for more studies. 
 
 
Supplem entary I nform at ion 
 
Additional Supporting Information may be found in the online version of this article: 
Table S1 . Clinical characteristics and pre-implantation evaluation of patients upgraded to CRT-D and 
CRT-P (n=2398) who were pacemaker-dependent or not. 
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Figure 1  Success rate of procedure in relation to upgrading from a previous device or de novo implantation. CRT, 
cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; PM, pacemaker. 
  
Figure 2  Upgrades in top 10 recruiting countries: cardiac resynchronization therapy-pacemaker (CRT-P) compared to 
cardiac resynchronization therapy-defibrillator (CRT-D). 
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Figure 1 ʹ Complications and major adverse events  
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leTable 1  Clinical characterist ics  Upgrades PM/ I CD ( n= 2 3 9 8 )  De novo ( n= 7 9 3 3 )  P- value Demographics      Age, years (IQR)  72 (6478)  69 (6276) <0.0001  
 Age >75 years  37.9% (909/2398)  30.2% (2398/7930) <0.0001  
 Female sex  18.8% (451/2398)  26.1% (2065/7927)  <0.0001  
 Currently enrolled in a trial  7.1% (169/2395)  8.6% (680/7915)  0.01665  
Primary aetiology      
 Ischaemic 48.2% (1147/2380) 43.7% (3448/7892) 0.046 
 Non-ischaemic  43.5% (1035/2380)  51.3% (4052/7892)   
 Other  8.3% (198/2380)  5.0% (392/7892)   
Previous history    
 Myocardial infarction  40.3% (957/2375)  35.2% (2777/7886)  <0.0001  
 PCI/CABG  43.1% (1023/2372)  37.8% (2979/7884)  <0.0001  
 Valvular disease  32.2% (764/2371)  25.3% (1998/7883)  <0.0001  
 Valvular surgery  36.5% (337/923)  28.7% (739/2571)  0.0001  
 Hypertension  65.5% (1550/2366)  63.6% (5003/7870)  0.08456  
 Diabetes  32.2% (763/2373)  31.2% (2463/7885)  0.39902  
 COPD 11.6% (275/2372)  12.0% (949/7885)  0.56049  
 Anaemia  16.8% (398/2371)  14.1% (1115/7881)  0.00150  
 GFR <60 mL/kg/min  40.9% (971/2375)  28.3% (2226/7869)  <0.00001  
 HF hospitalization <1 year  47.2% (1119/2371)  47.3% (3730/7881)  0.90895  
Atrial fibrillation  54.5% (1292/2369)  36.6% (2887/7884)  <0.00001  
 Paroxysmal  31.7% (409/1292)  36.3% (1049/2887)   
 Persistent  21.7% (281/1292)  22.8% (658/2887)   
 Permanent  45.8% (592/1292)  40.4% (1165/2887)   
 Missing  0.8% (10/1292)  0.5% (15/28879)   
Previous device*    
 PM  60.9% (1460/2398)  N/A   
 ICD  39.8% (955/2398)  N/A   
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; 
N/A, not applicable; PCI, percutaneous coronary intervention; PM, pacemaker. 
*More than one option could be chosen. 
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leTable 2  Pre- im plantat ion clinical evaluat ion and ECG  Upgrades PM/ I CD ( n= 2 3 9 8 )  De novo ( n= 7 9 3 3 )  P- value NYHA class   <0.00001  I 2.5% (60/2357) 3.5% (275/7829)  
 II 33.0% (778/2357) 38.4% (3009/7829)  
 III 59.1% (1392/2357) 53.9% (4223/7829)  
 IV  5.4% (127/2357)  4.1% (322/7829)   
BMI, kg/m2, median (IQR)  27 (2531) (n=2291) 27 (2430) (n=7551)  0.26781  
Systolic BP, mmHg, median (IQR) 120 (110134) (n=2326) 123 (110138) (n=7722) <0.00001 
Diastolic BP, mmHg, median (IQR) 70 (6580) (n=2324) 72 (6680) (n=7721) 0.00053 
Echocardiography    
 LVEF,% 30 (2234) (n=2342) 29 (2333) (n=7806) 0.3882 
 LVEF 35% 14.1% (331/2342) 11.5% (901/7806)  
 LVEDD, mm, median (IQR) 63 (5769) (n=1862) 63 (5869) (n=6293) 0.09855 
 Mitral regurgitation   0.00756 
  Mild 42.9% (940/2189) 47.7% (3443/7219)  
  Moderate 29.1% (637/2189) 26.0% (1875/7219)  
  Severe 7.9% (174/2189) 6.6% (1423/7219)  
  None 20.0% (1935/2189) 19.7% (1423/7219)  
Laboratory, median (IQR)    
 NT-proBNP, pg/mL 2811 (12646818) (n=848) 2228 (9845131) (n=2492) <0.00001 
 BNP, ng/L 479 (1641159) (n=283) 430 (1531127) (n=1016) 0.44957 
 Hb, g/dL 13 (1215) (n=2249) 138 (1215) (n=7408) 0.50769 
 SCr, ǋmol/L 108 (88139) (n=1356) 98 (82126) (n=4273) <0.00001 
Pre-implantation ECG    
 Heart rate, b.p.m., median (IQR) 70 (6576) 71 (6182) <0.00001 
 Atrial rhythm    
  Sinus rhythm 49.7% (1170/2354) 75.8% (5937/7829)  
  Atrial fibrillation 34.4% (810/2354) 22.9% (1791/7829)  
  Atrial paced 10.3% (243/2354) 0.1% (9/7829)  
  Other 5.6% (131/2354) 1.2% (92/7829)  
 PR interval, ms, median (IQR) 180 (157/215) 180 (160/210) 0.47623 
 AV block II/III,% 44.2% (1028/2327) 10.0% (770/7728) <0.00001 
Paced QRS duration, ms, median (IQR) 180 (160200) 178 (135191) 0.05004 
Intrinsic QRS duration, ms, median (IQR) 160 (140180) 160 (140171) 0.00002 
 <120 9.2% (123/1344) 7.3% (563/7738)  
 120130 6.0% (80/1344) 5.2% (401/7738)  
 130150 16.3% (219/1344) 19.1% (1479/7738)  
 150180 39.1% (526/1344) 48.7% (3772/7738)  
 >180 29.5% (396/1344) 19.7% (1523/7738)  
Intrinsic QRS morphology    
 LBBB 58.9% (1368/2323) 77.7% (6976/7822) <0.00001 
 RBBB 4.9% (137/2323) 7.3% (6569/7822) 0.00005 
 Indeterminable 17.1% (397/2323) 8.0% (626/7822) <0.00001 
 Normal 7.3% (170/2323) 7.3% (568/7822) 0.92658 
 Missing 11.9% (277/2323) 0.1% (4/7822)  
PM-dependent  51.9% (1213/2338) 0.4% (30/7767) <0.00001 
AV nodal ablation*   <0.00001 
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le Performed 47.6% (78/164) 12.9% (81/627)   Planned 52.4% (86/164) 87.1% (546/627)  Indication for CRT     HF wide QRS 52.1% (1240/2381) 63.1% (4964/7870) <0.00001 
 HF or LV dysfunction and an ICD indication 42.0% (1000/2381) 49.9% (3926/7870) <0.00001 
 PM indication and expected to be dependent 
 of RV pacing 
39.0% (929/2381) 17.4% (1368/7870) <0.00001 
 Mechanical dyssynchrony 12.8% (305/2381) 11.1% (872/7870) 0.02036 
 Other 6.7% (159/2381) 3.0% (240/7870) 0.02036 
AV, atrioventricular; BMI, body mass index; BP, blood pressure; BNP, B-type natriuretic peptide; CRT, cardiac resynchronization therapy; Hb, haemoglobin; IQR, interquartile range; HF, heart failure; ICD 
implantable cardioverter-defibrillator; LBBB, left bundle branch block; LV, left ventricular; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; NT-proBNP, N-terminal pro-
B-type natriuretic peptide; NYHA, New York Heart Association; PM, pacemaker; RBBB, right bundle branch block; RV, right ventricular; SCr, serum creatinine.  
*AV nodal ablation only regards patients with atrial fibrillation. 
More than one indication could be given.  
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leTable 3  Cardiac resynchronizat ion therapy im plantat ion procedure and peri- procedural com plicat ions  Upgrades PM/ I CD ( n= 2 3 9 8 )  De novo ( n= 7 9 3 3 )  P- value Admission     Elective admission  81.6% (1936/2374)  76.5% (6035/7884)  <0.0001  
 Referral  22.4% (532/2373)  26.3% (2065/7927  0.00013  
Successful implantation  97.1% (2349/2419)  97.3% (7780/7993)  0.54406  
Unsuccessful implantation  2.9% (70/2419)  2.7% (213/7993)   
Type of device    <0.00001  
 CRT-P  35.3% (828/2343)  28.6% (2224/7766)   
 CRT-D  64.7% (151572343)  71.4% (5542/7766)   
Operator    0.00318  
 Electrophysiologist  80.0% (1873/2341)  77.2% (5996/7770)   
 HF physician  4.9% (115/2341)  5.0% (388/7770)   
 Invasive cardiologist  10.2% (238/2341)  12.5% (971/7770)   
 Surgeon  4.0% (94/2341)  3.9% (305/7770)   
 Other  0.9% (21/2341)  1.4% (110/7770)   
Prophylactic antibiotics  98.9% (2291/2316)  98.6% (7588/7696)  0.23263  
Procedure time, min, median (IQR) 90 (65125)  90 (70120)   
Fluoroscopy time, min, median (IQR) 13 (723)  14 (822)   
LV lead type    <0.00001  
 Unipolar  0.6% (14/2313)  0.6% (44/7651)   
 Bipolar  45.2% (1046/2313)  40.0% (3059/7651)   
 Multipolar  54.2% (1253/2313)  59.4% (4548/7651)   
LV position optimized    0.00529  
 Electrical delay such as QLV  66.5% (457/687)  59.4% (1483/2495)   
 Paced QRS duration  52.4% (3357/681)  62.0% (1548/2496)   
 Other  22.8% (155/680)  24.8% (619/2491)   
Peri-procedural complications  5.1% (125/2430)  5.7% (461/8020)  0.25683  
 Death  0.0%  1.7% (8/461)   
 Any bleeding  29.6% (37/125)  14.1% (65/461)   
  Requiring intervention  41.7% (15/36)  26.2% (17/65)   
  Pocket haematoma  75.0% (27/36)  84.6% (55/65)   
 Pneumothorax  8.8% (11/125)  21.3% (98/461)   
 Haemothorax  2.4% (3/125)  1.3% (6/461)   
 Coronary sinus dissection  33.6% (42/125)  34.9% (161/461)   
 Pericardial tamponade  2.4% (3/125)  5.0% (23/461)   
 Other  30.4% (38/125)  24.9% (115/461)   
CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; IQR, interquartile range; HF, heart failure; ICD, implantable cardioverter-defibrillator; LV, left 
ventricular; PM, pacemaker. 
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leTable 4  Post - cardiac resynchronizat ion therapy im plantat ion  Upgrades PM/ I CD ( n= 2 3 9 8 )  De novo ( n= 7 9 3 3 )  P- value Post-implant ECG     Paced QRS duration, ms, median (IQR) 140 (129160) 134 (120150) <0.00001 
  Paced-intrinsic 20 (40 to 0) 20 (40 to 3) 0.00027 
  CRT-paced  40 (59 to 20)  N/A   
Device programming     
 AV optimization 52.4% (1206/2300) 59.3% (4533/7642) <0.0001 
 VV optimisation 51.3% (1178/2296) 57.8% (4414/7631) <0.00001 
 Device optimization  31.1% (712/2286)  37.6% (2846/7565)  0.00064  
Discharge state     
 Alive 99.7% (2348/2356) 99.6% (7790/7821) 0.69566 
 Dead  0.3% (8/2356)  0.4% (32/7821)   
Total length of hospital stay, days, median (IQR)  3 (26)  3 (27)  0.11462  
Major adverse events after the procedure 5.4% (129/2398) 4.4% (352/7933) 0.05496 
 Myocardial infarction 0.1% (2/2347) 0.1% (4/7801)  
 Stroke 0.1% (3/2347) 0.0%   
 Infection 0.6% (13/2347) 0.5% (38/7801)  
 Worsening HF 0.9% (21/2347) 0.7% (53/7801)  
 Worsening renal function 1.1% (26/2347) 0.9% (67/7801)  
 Arrhythmias 1.3% (46/2347) 1.2% (140/7801)  
 Other 2.0% (46/2347) 1.8% (140/7801)  
Planned follow-up  97.7% (2347/2398)  98.4% (7803/7933)  0.11043  
 Implanting centre 85.1% (1997/2398)  87.2% (6803/7803)   
 Other hospital  7.5% (177/2398)  8.1% (629/7803)   
 Private cardiologist  6.3% (148/2347)  5.0% (394/7803)  
 Primary care  1.0% (24/2398)  0.8% (65/7803)   
 CRT/pacemaker clinic  11.0% (257/2398) 10% (781/7803)   
 HF management clinic  2.7% (63/2347)  2.5% (193/7803)   
 Other  0.3% (7/2347)  0.3% (21/7893)   
Remote monitoring planned  30.1% (704/2339)  30.2% (2334/7727)  0.92100  
Drug therapy at discharge     
 ACEi/ARB  83.7% (1925/2299)  87.4% (6692/7659)  <0.00001  
 Beta-blocker  88.6% (2046/2308)  89.2% (6859/7692)  0.48089  
 MRA  60.1% (1377/2292)  64.6% (4934/7637)  0.00008  
 Digoxin  11.6% (266/2290)  9.8% (744/7611)  0.01073  
 Ivabradine  3.9% (90/2284)  6.2% (473/7616)  0.00004  
 Ca2+-channel-blocker 7.6% (507/2286) 15.7% (1198/7617) 0.03055 
 Amiodarone  22.2% (507/2286)  15.7% (1198/7617)  <0.00001  
 Oral anticoagulant  61.1% (1904/2303)  41.8% (3198/7642)  <0.00001  
  Warfarin 72.4% (1016/1404)  68.7% (2198/3198)  0.01338  
  Dabigatran  6.3% (89/1404)  6.8% (218/3198)  0.54982  
  Rivaroxaban  11.0% (154/1404)  13.4% (429/3198)  0.02162  
  Apixaban  10.1% (142/1404)  10.6% 338/3198)  0.64184  
  Edoxaban  0.2% (3/1404)  0.5% (15/3198)  0.20128  
 Antiplatelet agent  36.4% (874/2396)  46.7% (3706/7933)  <0.00001  
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; AV, atrioventricular; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter-
defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; N/A, not applicable; PM, pacemaker; VV, ventriculoventricular. 
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leTable 5  Com parison of pat ients upgraded from  a pacem aker or im plantable cardioverter- defibrillator to CRT- P or  CRT- D  Upgrade from  PM to CRT- P ( n= 8 0 2 )  Upgrade from  PM to CRT- D ( n= 5 9 5 )  Upgrade from  I CD to CRT- D ( n= 8 9 6 )  P- value*  Demographics     
 Age, years (IQR) 76 (6981) 72 (6576) 67 (6074) <0.00001 
 Age 75 years 57.0% (457/802) 34.3% (204/595) 22.7% (203/896)  
 Female sex  28.7% (230/802)  17.1% (102/595)  12.1% (108/896)  <0.00001  
 Currently enrolled in a trial  5.1% (41/801)  9.6% (57/594)  6.6% (59/895)  0.00437  
Primary aetiology     
 Ischaemic  31.9% (254/795)  49.5% (293/592)  61.6% (548/890)  <0.00001  
 Non-ischaemic 52.6% (418/795)  43.6% (258/592)  35.5% (316/890)   
 Other 15.5% (123/795)  6.9% (41/592)  2.9% (26/890)   
Previous history     
 Myocardial infarction 25.0% (198/792)  38.4% (227/591)  54.9% (488/889)  <0.00001  
 PCI/CABG 28.3% (224/791)  43.4% (256/590)  56.3% (500/888)  <0.00001  
 Valvular disease 34.4% (273/793)  32.1% (189/589)  30.5% (270/885)  0.22868  
 Valvular surgery 39.1% (129/330)  45.5% (102/224)  29.4% (96/327)  0.00037  
 Hypertension 68.0% (538/791)  67.6% (398/589)  61.8% (546/884)  0.01237  
 Diabetes mellitus 31.1% (247/794)  32.9% (194/589)  31.8% (282/887)  0.76978  
 COPD 11.2% (89/793)  13.1% (77/589)  11.4% (101/887)  0.51762  
 Anaemia 17.2% (136/793)  16.6% (98/589)  16.3% (144/885)  0.88992  
 GFR <60 mL/kg/min 41.8% (331/792)  33.4% (198/592)  43.7% (388/887)  0.00024  
 HF hospitalization <1 year 45.6% (361/792)  44.0% (259/589)  50.3% (446/886)  0.03386  
Atrial fibrillation 57.6% (456/792)  56.9% (335/589)  49.4% (437/884)  <0.00001  
 Paroxysmal 27.4% (125/456)  29.6% (99/335)  38.9% (170/437)   
 Persistent 20.4% (93/456)  20.3% (68/335)  26.1% (114/437)   
 Permanent 51.8% (236/456)  49.0% (164/335)  34.6% (151/437)   
 Missing 0.4% (2/456)  1.2% (4/335)  0.5% (2/437)   
Pre-implantation evaluation     
 NYHA class     
  I 2.9% (23/791)  2.9% (17/586)  1.9% (17/881)  0.00002  
  II 27.9% (221/791)  38.7% (227/586)  33.9% (299/881)   
  III 62.3% (493/791)  55.8% (327/586)  58.1% (512/881)   
  IV 6.8% (54/791)  2.6% (15/586)  6.0% (53/881)   
Pre-implantation ECG atrial rhythm     
 Sinus rhythm 41.8% (329/787)  39.6% (233/588)  65.2% (574/881)  <0.00001  
 Atrial fibrillation 40.3% (317/787)  35.7% (210/588)  27.1% (239/881)   
 Atrial paced 13.0% (102/787)  15.6% (92/588)  4.3% (38/881)   
 PR interval, ms, median (IQR) 176 (142200)  169 (150200)  198 (164228)  <0.00001  
 Intrinsic QRS, ms, median (IQR) 160 (136180) (n=313) 160 (140180) (n=271) 160 (140180) (n=709) 0.51657  
LVEF,%, median (IQR) 30 (2536)  30 (2533)  25 (2030)  <0.00001  
Peri-procedural complications 4.4% (36/810)  6.0% (36/596)  4.9% (44/904)  0.38528  
 Death 0.0% (0/36)  0.0% (0/36)  0.0% (0/44)   
 Bleeding 30.6% (11/36)  36.1% (13/36)  25.0% (11/44)   
  Requiring intervention 36.4% (4/11)  50.0% (6/12)  45.5% (5/11)   
  Pocket haematoma 63.6% (7/11)  83.3% (10/12)  72.7% (8/11)   
 Pneumothorax  5.6% (2/36)  8.3% (3/36)  13.6% (6/44)   
 Haemothorax  2.8% (1/36)  2.8% (1/36)  2.3% (1/44)   
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le Coronary sinus dissection  33.3% (12/36)  25.0% (9/36)  31.8% (14/44)    Pericardial tamponade  2.8% (1/36)  0.0% (0/36)  4.5% (2/44)    Other  33.3% (12/36)  33.3% (12/36)  29.5% (13/44)   CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; GFR, 
glomerular filtration rate; IQR, interquartile range; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; PM, pacemaker. 
*For statistical significance the non-parametric KruskalWallis test was used when appropriate.  
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